$OPTX secured a $4.6M purchase order
for the continued manufacturing of laser blood-test cartridges and optical reader subsystems.
These devices are deployed in ICUs, neonatal ICUs, operating rooms and emergency departments across global hospitals and clinics.
They test hemoglobin, electrolytes and metabolites, mission-critical point-of-care diagnostics.
> Half the order has already shipped
> Full delivery by Q3
CFO Dean Rudy said it himself: "our BioMed product lines continue to anchor the business with stable, diversified, recurring orders for products with long life cycles"
That's the part the market keeps missing on
$OPTX
Everyone is watching the defense contracts and LEO satellite optics. Nobody is talking about the recurring, predictable biomedical revenue sitting underneath, a product line with decades of operational history quietly funding the space and defense growth.
The opticals thesis has multiple legs.